@Article{Czekierdowski2007,
journal="Menopause Review/Przegląd Menopauzalny",
issn="1643-8876",
volume="6",
number="3",
year="2007",
title="The assessment of angiogenic factors VEGF, VEGFR-2 and VCAM-1 in the serum of women  with malignant ovarian tumours before and after the menopause",
abstract="  Aim:  The aim of this study was to evaluate preoperative serum concentrations of selected soluble angiogenic cytokines in women with malignant ovarian tumours.   Material and methods:  we investigated clinical and pathological characteristics of 77 women (43 after the menopause) with ovarian cancer and compared the results with VEGF, VEGFR-2 (receptor to VEGF, type 2) and VCAM-1 serum concentrations using the ELISA method and R\&D Systems (USA) kits. The differences were compared with chi square test.    Results:  Serum concentrations of VEGF and VEGFR-2 were higher in women after menopause (Z=\–1.9; p=0.054 for VEGF and Z=\–1.71; p=0.08 for VEGFR-2). Neither tumour histological grade nor FIGO clinical stage were related to the measured concentrations of these soluble cytokines. VCAM-1 concentration was not different between the groups of pre- and postmenopausal women. The highest concentrations of VCAM-1 were found in a subgroup of low histological grade and FIGO stage 3-4 tumours and the differences between these women and patients with high grade tumours and/or FIGO stage 1-2 cancers were statistically significant (H=10.7; p=0.004 and H=17.4; p=0.0006, respectively).   Conclusion:  Measurements of the soluble forms of VEGF and VEGFR-2 in blood serum are probably not useful in preoperative malignant ovarian tumour management. VCAM-1 concentrations may be of value as an additional marker of ovarian cancer angiogenic characteristics, possibly related to histological grade and clinical stage.",
author="Czekierdowski, Artur
and Czekierdowska, Sylwia",
pages="128--133",
url="https://www.termedia.pl/The-assessment-of-angiogenic-factors-VEGF-VEGFR-2-and-VCAM-1-in-the-serum-of-women-with-malignant-ovarian-tumours-before-and-after-the-menopause,4,8618,1,1.html"
}